SCRI Development Innovations, LLC: Breast Neoplasms trials

The registry lists 34 Breast Neoplasms studies with SCRI Development Innovations, LLC as lead sponsor. 1 are open to participants now and 26 have results posted.

Phase 1 4Phase 2 28Phase 3 2No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast CancerRecruitingNCT05748834Phase 2
• A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast CancerCompletedNCT04699630Phase 2Results posted
• Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast CancerCompletedNCT02291913Phase 2Results posted
• Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)CompletedNCT01990209Phase 2Results posted
• Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial MetastasesTerminatedNCT01934894Phase 2Results posted
• Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast CancerCompletedNCT01527487Phase 2Results posted
• Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast CancerCompletedNCT01048099Not applicableResults posted
• Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast CancerCompletedNCT01033032Phase 1/2Results posted
• Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast CancerCompletedNCT00915603Phase 2Results posted
• Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast CancerCompletedNCT00894504Phase 2Results posted
• Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast CancerCompletedNCT00887575Phase 1/2Results posted
• Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast CancerCompletedNCT00866905Phase 2Results posted
• Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast CancerCompletedNCT00825734Phase 1/2Results posted
• Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast CancerCompletedNCT00821886Phase 2Results posted
• A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast CancerCompletedNCT00789581Phase 3Results posted
• LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer PatientsCompletedNCT00632489Phase 1Results posted
• Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast CancerCompletedNCT00629499Phase 2Results posted
• Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast CancerCompletedNCT00544167Not applicableResults posted
• Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast CancerCompletedNCT00405938Phase 2Results posted
• Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast CancerCompletedNCT00392392Phase 2Results posted
• Trastuzumab and Oxaliplatin in Patients With Metastatic Breast CancerCompletedNCT00297596Phase 2Results posted
• Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast CancerCompletedNCT00284180Phase 2Results posted
• Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast CancerCompletedNCT00193206Phase 2Results posted
• Docetaxel Plus Imatinib Mesylate in Metastatic Breast CancerCompletedNCT00193180Phase 2Results posted
• Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast CancerCompletedNCT00193063Phase 2Results posted
• Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast CancerCompletedNCT00193050Phase 2Results posted
• Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast CancerCompletedNCT00193037Phase 2Results posted
• Community Oncology Setting Cost Analysis and Disease Outcomes of Taxane Use in Metastatic Breast CancerCompletedNCT00876070
• Docetaxel Followed by Doxorubicin Plus Cyclophosphamide for Node Positive or High-Risk Primary Breast CancerCompletedNCT00193115Phase 2
• Thalidomide in Combination With Capecitabine in Patients With Metastatic Breast CancerTerminatedNCT00193102Phase 2
• Docetaxel, Vinorelbine and Trastuzumab in the Treatment of Patients With Metastatic Her-2 Positive Breast CancerCompletedNCT00193089Phase 2
• Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast CancerCompletedNCT00193076Phase 2
• Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast CancerTerminatedNCT00193024Phase 2
• Weekly Docetaxel and CMF in the Adjuvant Treatment of Elderly Women With High-Risk Breast CancerCompletedNCT00193011Phase 3